-
Something wrong with this record ?
Cannabidiol disrupts tryptophan metabolism in the human term placenta
R. Portillo, C. Abad, T. Synova, P. Kastner, D. Heblik, R. Kucera, R. Karahoda, F. Staud
Language English Country Ireland
Document type Journal Article
- MeSH
- Cannabidiol * pharmacology MeSH
- Kynurenine metabolism MeSH
- Humans MeSH
- Placenta * metabolism drug effects MeSH
- Serotonin * metabolism MeSH
- Pregnancy MeSH
- Tryptophan * metabolism MeSH
- Check Tag
- Humans MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
The increasing use of cannabis during pregnancy raises concerns about its impact on fetal development. While cannabidiol (CBD) shows therapeutic promise, its effects during pregnancy remain uncertain. We investigated CBD's influence on tryptophan (TRP) metabolism in the human placenta. TRP is an essential amino acid that is metabolized via the serotonin and kynurenine (KYN) pathways, which are critical for fetal neurodevelopment. We used human term villous placental explants, an advanced ex vivo model, to study CBD's impact on key TRP metabolic enzymes. In addition, vesicles isolated from the microvillous membrane (MVM) of the human placenta were used to assess CBD's effect on placental serotonin uptake. Explants were exposed to CBD at therapeutic (0.1, 1, 2.5 μg/ml) and non-therapeutic (20 and 40 μg/ml) concentrations to determine its effects on the gene and protein expression of key enzymes in TRP metabolism and metabolite release. CBD upregulated TRP hydroxylase (TPH) and downregulated monoamine oxidase (MAO-A), resulting in reduced levels of 5-hydroxyindoleacetic acid (HIAA). It also downregulated serotonin transporter expression and inhibited serotonin transport across the MVM by up to 60% while simultaneously enhancing TRP metabolism via the kynurenine pathway by upregulating indoleamine-pyrrole 2,3-dioxygenase (IDO-1). Among kynurenine pathway enzymes, kynurenine 3 monooxygenase (KMO) was upregulated while kynurenine aminotransferase 1 (KAT-1) was downregulated; the former is associated with neurotoxic metabolite production, while the latter is linked to reduced neuroprotective metabolite levels. Overall, these results indicate that CBD modulates TRP catabolism in the human placenta, potentially disrupting the tightly regulated homeostasis of the serotonin and KYN pathways.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013669
- 003
- CZ-PrNML
- 005
- 20240905133552.0
- 007
- ta
- 008
- 240725e20240423ie f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.tox.2024.153813 $2 doi
- 035 __
- $a (PubMed)38663822
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ie
- 100 1_
- $a Portillo, Ramon $u Department of Pharmacology and Toxicology, Charles University, Faculty of Pharmacy in Hradec Kralove, Czech Republic
- 245 10
- $a Cannabidiol disrupts tryptophan metabolism in the human term placenta / $c R. Portillo, C. Abad, T. Synova, P. Kastner, D. Heblik, R. Kucera, R. Karahoda, F. Staud
- 520 9_
- $a The increasing use of cannabis during pregnancy raises concerns about its impact on fetal development. While cannabidiol (CBD) shows therapeutic promise, its effects during pregnancy remain uncertain. We investigated CBD's influence on tryptophan (TRP) metabolism in the human placenta. TRP is an essential amino acid that is metabolized via the serotonin and kynurenine (KYN) pathways, which are critical for fetal neurodevelopment. We used human term villous placental explants, an advanced ex vivo model, to study CBD's impact on key TRP metabolic enzymes. In addition, vesicles isolated from the microvillous membrane (MVM) of the human placenta were used to assess CBD's effect on placental serotonin uptake. Explants were exposed to CBD at therapeutic (0.1, 1, 2.5 μg/ml) and non-therapeutic (20 and 40 μg/ml) concentrations to determine its effects on the gene and protein expression of key enzymes in TRP metabolism and metabolite release. CBD upregulated TRP hydroxylase (TPH) and downregulated monoamine oxidase (MAO-A), resulting in reduced levels of 5-hydroxyindoleacetic acid (HIAA). It also downregulated serotonin transporter expression and inhibited serotonin transport across the MVM by up to 60% while simultaneously enhancing TRP metabolism via the kynurenine pathway by upregulating indoleamine-pyrrole 2,3-dioxygenase (IDO-1). Among kynurenine pathway enzymes, kynurenine 3 monooxygenase (KMO) was upregulated while kynurenine aminotransferase 1 (KAT-1) was downregulated; the former is associated with neurotoxic metabolite production, while the latter is linked to reduced neuroprotective metabolite levels. Overall, these results indicate that CBD modulates TRP catabolism in the human placenta, potentially disrupting the tightly regulated homeostasis of the serotonin and KYN pathways.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a těhotenství $7 D011247
- 650 12
- $a tryptofan $x metabolismus $7 D014364
- 650 12
- $a placenta $x metabolismus $x účinky léků $7 D010920
- 650 12
- $a kanabidiol $x farmakologie $7 D002185
- 650 12
- $a serotonin $x metabolismus $7 D012701
- 650 _2
- $a kynurenin $x metabolismus $7 D007737
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Abad, Cilia $u Department of Pharmacology and Toxicology, Charles University, Faculty of Pharmacy in Hradec Kralove, Czech Republic
- 700 1_
- $a Synova, Tetiana $u Department of Pharmacology and Toxicology, Charles University, Faculty of Pharmacy in Hradec Kralove, Czech Republic
- 700 1_
- $a Kastner, Petr $u Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Charles University, Faculty of Pharmacy in Hradec Kralove, Czech Republic
- 700 1_
- $a Heblik, Daniel $u Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Charles University, Faculty of Pharmacy in Hradec Kralove, Czech Republic
- 700 1_
- $a Kucera, Radim $u Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Charles University, Faculty of Pharmacy in Hradec Kralove, Czech Republic
- 700 1_
- $a Karahoda, Rona $u Department of Pharmacology and Toxicology, Charles University, Faculty of Pharmacy in Hradec Kralove, Czech Republic
- 700 1_
- $a Staud, Frantisek $u Department of Pharmacology and Toxicology, Charles University, Faculty of Pharmacy in Hradec Kralove, Czech Republic. Electronic address: frantisek.staud@faf.cuni.cz
- 773 0_
- $w MED00004533 $t Toxicology $x 1879-3185 $g Roč. 505 (20240423), s. 153813
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38663822 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133546 $b ABA008
- 999 __
- $a ok $b bmc $g 2143453 $s 1225535
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 505 $c - $d 153813 $e 20240423 $i 1879-3185 $m Toxicology $n Toxicology $x MED00004533
- LZP __
- $a Pubmed-20240725